Can an antiviral drug protect hearing in infants with congenital CMV?
Disease control
Stopped early
This trial tests whether the antiviral drug valganciclovir can improve hearing and language outcomes in infants who have hearing loss due to congenital cytomegalovirus (CMV) infection. Infants aged 1 to 12 months with confirmed sensorineural hearing loss will receive either valga…
Phase 2 • Sponsor: Albert Park • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC